Turquoise Plato Connects to OpenFin to Simplify Complexity on the Buy-Side Trader Desktop
21.9.2021 10:00:00 EEST | Business Wire | Press release
OpenFin, the operating system (OS) for enterprise productivity, today announced that LSEG’s (London Stock Exchange Group) Turquoise Plato is connecting to OpenFin in response to the industry need for workflow efficiencies, application interoperability, and a more unified desktop experience for the buy-side and member firm users.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210921005467/en/
Turquoise has a proven track record in delivering innovation and liquidity opportunities to the market, with Turquoise Plato Block Discovery™ having seen record levels of block trading activity on Turquoise® and Turquoise Europe™ in 2020. With this collaboration, Turquoise is continuing to deliver on its mission to identify efficient, collaborative operating models that reduce the implicit cost of trading, contribute to long-term investment returns and drive sustainable growth.
Turquoise on OpenFin™ delivers an insightful data feed directly into trader workflows to support liquidity discovery and decision making processes leveraging OpenFin’s open architecture. The API passes FDC3 compliant Context objects, and makes use of OpenFin’s message bus to pass that data to OpenFin-enabled applications including visualisation tools, in-house and 3rd party applications.
Dr Robert Barnes, Group Head of Securities Trading & CEO of Turquoise Global Holdings, LSEG, said: “As a market operator, Turquoise is well positioned to bring the industry together around a common ambition: to collaborate, innovate and to improve efficiencies on traders’ desktops. This will not only support best execution efforts but also improve performance for end investors as it helps us reduce the slippage cost at the point of execution. We are delighted Turquoise® and Turquoise Europe™ are the first trading venues to connect to OpenFin and offer this new functionality to the buy-side.”
Adam Toms, European CEO of OpenFin, commented: “We are witnessing a continued shift towards more collaborative mindsets and platforms. With forward thinking firms such as Turquoise working with the industry to create solutions that make the financial desktop more intuitive, automated and powerful, firms can unlock the true potential of interoperability and contextual workflows on their financial desktop. Operational complexity and costs arising from bilateral integrations are fast becoming a thing of the past as users can now access the right tools and data sets, surfaced directly into their workflows, delivering powerful capabilities and tangible results.”
Toms added: “Collaboration and innovation are central to our mission to simplify app distribution, unify the digital workspace and enable seamless communication and workflows between applications. We are very excited to be working with Turquoise to bring new, visionary models of collaboration to life and to market.”
OpenFin provides a common web-based OS layer across the financial services industry to power next-generation applications and desktop experiences. OpenFin technology is deployed on 300,000 desktops across the industry, powering over 3,500 applications in more than 2,400 buy-side and sell-side firms in 60+ countries.
FlexTrade Systems will be the first to deliver the Turquoise data feed into their flagship EMS via the OpenFin message bus. Traders can then act on that data, automate processes and take advantage of emerging liquidity opportunities. Built-in visualisation capabilities ensure the block trading activity from Turquoise Plato Order Books™ is easy to digest and subsequently interact with.
Andy Mahoney, Managing Director, EMEA at FlexTrade Systems, added: “We are delighted to work with Turquoise and OpenFin to support liquidity discovery and execution opportunities, and bring tangible benefits to the buy-side trading desk. It helps our clients customise their execution workflows, perform optimally on every trade and achieve best execution without compromise.”
About OpenFin
Move Fast. Break Nothing. OpenFin is the operating system for enterprise productivity, enabling app distribution, workspace management and workflow automation. Used by 90% of global financial institutions, OpenFin deploys more than 3,500 desktop applications to more than 2,400 buy-side and sell-side firms. OpenFin investors include Bain Capital Ventures, Barclays, CME Ventures, DRW Venture Capital, HSBC, J.P. Morgan, NYCA Partners, Pivot Investment Partners, Standard Chartered and Wells Fargo Strategic Capital among others. The company is based in New York with an office in London and presence in Hong Kong.
About FlexTrade
FlexTrade Systems is a global leader in high performance multi-asset execution management and order management systems for equities, fixed income, foreign exchange, futures, and options. A pioneer in the field, FlexTrade is internationally recognized for introducing FlexTRADER®, the world’s first broker-neutral, execution management trading system, which allows clients to completely control and customize their execution workflows through a comprehensive ability to search/access liquidity while maintaining the confidentiality of their trading strategies.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210921005467/en/
Contact information
Media
Sybille Mueller Streets Consulting
E: sybille.mueller@streetsconsulting.com
T: 020 7959 2235
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Plus Expands Relationship with SS&C to Support Cross-Border Operations in APAC3.8.2026 04:00:00 EEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that First Plus Asset Management (FPAM), a multi-asset investment management firm, has selected SS&C to provide cross-border operations support across Asia. SS&C will service First Plus across the full investment lifecycle, delivering a scalable, integrated solution supporting transfer agency, order management and execution and investment accounting. FPAM will utilize SS&C to service its growing cross-border operating model and support around $200 million in assets under management*. “As First Plus has expanded, managing our operations has become increasingly complex,” said Jeb Li, Co-Founder and CEO at First Plus. “SS&C’s global footprint and integrated offerings enable us to easily optimize our workflows, so we can focus on scaling quickly and securely while continuing to deliver risk-adjusted returns and best-in-class client service.” The engagement highlights the breadth and scalability of SS&C’s global service model.
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 11:01:00 EEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom